### CURRICULUM VITAE

Name:	Sabah H. Akrawi
Address:	College of Clinical Pharmacy
	King Faisal University, Al Ahsa - KSA
Telephone:	+1 510 724 3770
•	+1 510 758 7840
	+966 504922094
E-Mail:	shakrawi51@yahoo.com
	shakrawi@hotmail.com
	sakrawi@kfu.edu.sa

Associate Professor of Clinical Pharmacokinetics, Biopharmaceutics

Teaching under- graduate and post-graduate courses in Biopharmaceutics,

Pharmacokinetics, Clinical Pharmacokinetics, and Physical Pharmacy over 20 years.

Supervised more than 17 Post-Graduate students

Head of the Bioequivalence Studies Unit, Principal Investigator for the Bioequivalence Studies, and Head of the Analytical Laboratory, College of Pharmacy, Applied Science University, Amman-Jordan and College of Pharmacy Baghdad University. Conducted more than 18 bioequivalence studies

**Expert in:** 

- HPLC, GC & other laboratories technique. Conducting Chronic Intrahepatic & IV drug infusion in unrestrained animals. Conducting intranasal administration of drugs. Development and Validation of analytical methods for drugs using Micro Samples of blood.
   Design and Supervision of clinical studies.
   Design and Supervision of Disposition studies of drugs using Micro Samples.
   Drug Metabolism & its Stereo selective Disposition.
   Design and Supervision of Drug-Drug and Drug-Food interaction studies.
   Microsoft Word
   Microsoft Excel
- PowerPoint
   WinNonMix
   SPSS

EDUCATION	
1968–1973	BSc, College of Pharmacy
	University of Baghdad, Iraq
1982-1988	Ph.D. College of Pharmacy, University of Kentucky/ USA
	Dissertation Title:
	"Use of chronic portal vein infusion in rats to examine mephenytoin stereoselective disposition"
	-

### **Teaching interests:**

Teaching under- and post- graduate School of Pharmacy students courses of Clinical Pharmacokinetic, Pharmacokinetic, Physical Pharmacy, Biopharmaceuticals, Metabolism, Applied Therapeutic, OTC and Clinical Pharmacy.

#### Summary of research interests:

Research activities included the determination and evaluation of drug concentration to detect its relationship of the pharmacokinetic parameters to the therapeutic effects and pharmaceutical dosage form. Moreover, performed and validated drug analytical method. For instance; the evaluation and interpretation of the pharmacokinetic parameters of drugs (AUC, Clearance, T<sub>1/2</sub>, K<sub>e</sub>, K<sub>m</sub>, C<sub>max</sub>, T<sub>max</sub>, V<sub>d</sub> ...etc.); Pharmacokinetic/ Pharmacodynamics relationship. In addition, drugs under investigations required studies to determine their disposition, stereoslective disposition, through renal or metabolic route of elimination, additionally, its absorption and distribution in various body tissues. Effect of Drug–Drug and Drug–Food interaction on the disposition and its effect on pharmacokinetic parameters; bioavailability and bioequivalence studies include three parts the clinical, analytical and data statistical analysis; using micro sampling technique and the chronic intra hepatic infusion of drugs in unrestrained animals to predict the drug disposition and concentration profile.

### PROFESSIONAL EXPERIENCE

2012- Now	College of Clinical Pharmacy-King Faisal University
	Job Title: Associate Professor
	Responsibilities:
	1-Teaching School of Pharmacy students Clinical Pharmacokinetics &
	Pharmaceutical Care.
	2- Scientific research regarding Biopharmaceutics and
	Pharmacokinetics.
	3- Member of the scientific council -King Faisal University
	4- Member of the Translation, Authority, and Publication Center-KFU
	5- Recruitment Committee - coordinator
	6- Accreditation Committee - member
2010-2012	Al Ain University of Science and Technology
	Job Title: Associate Professor

	Responsibilities:
	1-Teaching School of Pharmacy students Biopharmaceutic, Pharmacy
	Practice Social & Behavioral Aspects of Pharmacy Practice
	Medication Dispensing and Distribution System & Physical Pharmacy
	2- Head of the Curriculum Committee
	3- Head of the Training Committee
	3- Scientific research regarding Bionharmaceutics and
	Pharmacokinetics
2000 2010	Al Zutoonah University Jordan
2009-2010	Al Zytoonan Oniversity – Jordan
	Job Title. Associate Professor
	Responsibilities:
	1-Teaching School of Pharmacy students Biopharmaceutic,
	Pharmaceutics, Pharmacokinetic, Clinical Pharmacokinetic & Physical
	Pharmacy.
	2- Head of the Scientific Committee, Curriculum organization
	3- Scientific research regarding Biopharmaceutics and
	Pharmacokinetics.
2000-2008	Applied Science University/College of Pharmacy, Amman-Jordan
	Job Title: Associate Professor
	Responsibilities:
	1-Teaching School of Pharmacy students Biopharmaceutic,
	Pharmacokinetic, Clinical Pharmacokinetic & Physical Pharmacy.
	2-Head of the Scientific and Curriculum committee at the School of
	Pharmacy.
	3-Principal investigator for Bioavailability studies.
	- Established Bioequivalence studies unit.
	- Designed and supervised four Bioequivalence studies
	(Clindamycin capsule, Ibuprofen suspension, Rifampicin 150 mg
	cansule and Rifampicin 300 mg cansule)
	- Provided and modified the analytical methods
	4-Head of the analytical laboratories for the Bioequivalence Unit
	responsible for drugs analysis
	5-Supervised three postgraduate students with different projects of my
	interest
	- "Two–Way, Crossover Randomized Bioequivalence Study of Two
	Formulations Containing rifampicin"
	"Effect of henetic blood flow on diurnal variation of CB7 steady
	- Effect of hepatic blood flow on diditial variation of CDZ steady
	State level during enforce portar veni infusion in fats.
	- Lishiopin versus Captopin in hypertensive patients with and
1006 2000	Without renai impairment.
1996-2000	University of Baghdad/ College of Pharmacy, Baghdad, Iraq
	Job Title: Associate Professor, Department of Clinical Pharmacy and
	Assistant to the Dean for Scientific Affair
	Responsibilities:
	1- Teaching School of Pharmacy students (under- and post- graduate)
	Pharmacokinetic, Clinical Pharmacokinetic, Biopharmaceutic &

	Physical Pharmacy.
	2- Member of the Post Graduate Studies Committee, Supervised post
	graduate students.
	3- Head of the Scientific and Curriculum committee at the School of
	Pharmacy.
	4- Principal investigator for Bioavailability studies.
	- Designed and supervised fourteen Bioequivalence studies
	(Cephalexin caps, Glibenclamide tablet, Naproxen tablet,
	Indomethacin capsule, Indomethacin suppositories, Clomipramine
	tablet. Amoxicillin Suspension. Ampicillin capsule.
	Carbidopa/Livodopa tablet. Gliclazide tablet. Methyldopa tablet and
	Clindamycin capsule).
	- Provided and modified the analytical methods
	5- Head of the analytical laboratories for the Bioequivalence Unit
	responsible for drugs analysis
	6- Supervised ten post-graduate students with different projects of my
	interest
	- "The effect of prednisolone and antibiotic treatment on sperm
	function test and sperm agolutination in infertile men"
	- "Determination of nifedinine concentration in human serum"
	- "Two-Way, Crossover Randomized Bioequivalence Study of Two
	- Two-way, Crossover Kandolinzed Dioequivalence Study of Two Formulations Containing 5mg Glibenelamide and Treatment
	Monitoring"
	"The biographility biogging and study of two desage forms of
	- The bloavallability-bloequivalence study of two dosage forms of test indemethasin product (25 mg sangulas & 100 mg suppositorios)
	and the treatment monitoring on nationts using it?
	"A two way grossover bioavailability bioaguivalance study for
	- A two-way clossover bloavallability - bloequivalence study for
	"Drug registration system"
	- Diug registration system "Thereprovide drug monitoring for a test product containing 100mg
	- Therapeutic drug monitoring for a test product containing fooring
	"Comparative study of three different manufacturers of atopolol
	tablets in hypertensive nations?
	- "Possible drug interaction between carbamazenine and tea
	components in human"
	- "Prescribing errors in selected Hosnital and Private Clinics in
	Baghdad"
	Dublique
1988-1996	University of Baghdad/ College of Pharmacy, Baghdad, Iraq
	Job Title: Assistant Professor. Department of Clinical Pharmacv
	Responsibilities:
	1- Teaching School of Pharmacy students (under- and post- graduate)
	Pharmacokinetic, Clinical Pharmacokinetic, Biopharmaceutics &
	Physical Pharmacy.
	2- Member of the Post Graduate Studies Committee Supervised post
	graduate students.

	3- Principal investigator for Bioavailability studies.
	- Established Bioequivalence studies unit.
	- Design and supervised one Bioequivalence study (Atenolol tablet)
	- Provide and modify its analytical method
	4- Head of the analytical laboratories for the Bioequivalence Unit,
	responsible for drugs analysis.
	5- Supervised four postgraduate students with different projects of my
	interest:
	- "Characterization of diurnal variation during chronic intravenous
	infusion of carbamazepine in rats"
	- "Prescribing errors in hospitals and private clinics in Kurkuk city"
	- "Determination of renal stone's type affected by Prosopis Farcta
	leaves extract"
	- "Nosocomial infections in three of Erbl's Hospitals"
1978-1982	University of Baghdad/ College of Pharmacy, Baghdad, Iraq
	Job Title: Assistant to the Dean for Student Affair
	Responsibilities:
	1- Administration & Registration for the School of Pharmacy students
	2- Supervise and Control the application of the curriculum.
	3- Supervise the Pharmacy students training
1975-1978	University of Baghdad/ College of Pharmacy, Baghdad, Iraq
	Job Title: Instructor
	Responsibilities: Dept. of Pharmacology
PUBLICATION	S
	1. "A problem with quantitation of mephenytoin enantiomers due
	to chiral interference from N-demethylated metabolite": Sabah H.
	Akrawi and Peter J. Wedlund; J. chromatography, 381, 198-200,
	1986.
	2. "Method for chronic portal vein infusion in unrestrained rats":
	Sabah H. Akrawi and Peter J. Wedlund; J. Pharmacological
	Methods; 17, 67-74 1987.
	3. "Use of chronic portal vein infusion in rats to examine
	mephenytoin stereoselective disposition" Sabah H. Akrawi, a PhD
	dissertation, College of Pharmacy, University of Kentucky,
	Lexington, KY, USA, 1988.
	4. "Mephenytoin stereoselective elimination in the rats: I-
	Enantiomeric disposition following intravenous administration".
	Sabah H. Akrawi and Peter J. Wedlund, European J. of drug
	metabolism and pharmacokinetics; Vol. 14, No. 3 pp. 195-200;
	1989.
	5. "Mephenytoin stereoselective elimination in the rats: II-
	Comparison of mephenytoin stereoselective clearance during
	chronic intravenous and hepatic portal vein administration". Sabah
	H. Akrawi and Peter J. Wedlund, European J. of drug metabolism
	and pharmacokinetics; Vol. 14, No. 4, pp. 269-278; 1989.

6. "Mephenytoin stereoselective elimination in the rats: III.
Stereoselective time course of induction during chronic hepatic
portal vein administration". Sabah H. Akrawi and Peter J. Wedlund,
European J. of drug metabolism and pharmacokinetics; European J.
of drug metabolism and pharmacokinetics; 1989.
7. "Tissue distribution of INDIUM-III labeled poly (Glycolic
Acid) matrices following jugular and hepatic portal vein
administration". A.M. Hazrati, S. Akrawi, A.J. Hicky, P. Wedlund,
J. Macdonald and P.P. Deluca, J. of Controlled Release, 9, pp. 205-
214,1989.
8. "The effect of alphatoccopherol on experimentally induced
gentamicin nephrotoxicity in rats". Abdulla T.M. Al-Ani, Marwan
S.M. Al-Nimer and Sabah H. Akrawi, Iragi J. Pharm. Sci. Vol 5(1)
1994.
9. "Nosocomial infections in three of Erbl's Hospitals". Kawa F.
Dizavee and Sabah H. Akrawi. Iraqi J. Pharm. Sci. Vol. 6(1) 1995.
10. "Effect of molsidomine on trace metals in gentamicin induced
nephrotoxicity in rats". Sabah H. Akrawi, Faris S. Allah-Werdi and
Marwan S.M.Al-Nimer, Iraqi J. Pharm. Sci. Vol. 6(1) 1995.
11. "Prescribing errors in selected Hospital and Private Clinics in
Baghdad". Sabah H. Akrawi, Iragi J. Pharm. Sci. Vol. 7 1996.
12. "The evaluation of renoprotective effect of L-carnitine against
gentamicin nephrotoxicity". Sabah H. Akrawi. Iraqi J. Pharm. Sci.
Vol. 7 1996.
13. "Changes in brain glucose and glycogen in epileptic mice",
S.P. Jazrawi and S.H. Akrawi, Al-Buhooth Al Tachaniya, Vol 9
,N0 33, 1996.
14. "Effect of L-carnitine on lipid peroxidation in gentamicin
induced nephrotoxicity in rats". Marwan S.M. Al-Nimer, Sabah H.
Akrawi, Suhad Kh, Al-Jubory. Iraqi J. Pharm. Sci. Vol. 8(1) 1997.
15. "Potentaition of Gentamicin Induced Nephrotoxicity by
Molsidomine in Rats". Sabah H. Akrawi and Marwan S.M. Al-
Nimer, Iraqi J. Pharm. Sci. Vol, (9) 1998.
16. "Bioavailability – Bioequivalency study of a formulation
containing Cephalexin", Sabah H. Akrawi, The Iraqi Journal of
Community Medicine, 2000.
17. "Bioequivalence Assessment of Doloraz <sup>®</sup> 100 mg
Suspensions in Healthy Human Volunteers". Sabah H. Akrawi,
Ziad Al-Talla', Sabah D. Salim and Loay Rashan. Iraqi Journal of
Pharmacy, Vol 3. No. 1, 2003.
18. "Bioequivalence study of indomethacin test product (25 mg
capsule)" Haidar F. Hadi. Sabah H. Akrawi and Salim A. Hamadi,
Iraqi J. Pharm Sci, vol 13. 2002.
19. "Bioequivalence Assessment of Clindox" 150 mg Capsules in
Healthy Human Volunteers". Sabah H. Akrawi, Ziad Al-Talla',
Sabah D. Salim and Loay Rashan. Iraqi Journal of Pharmacy, Vol 3.

	No. 1, 2003.	
	20. 'Bioequivalence Assessment of Hypoten <sup>®</sup> 100 mg Tablets in	
	Healthy Human Volunteers and Treatment Monitoring'. Sabah H.	
	Akrawi, Iraqi Journal of Pharmacy, Vol 3. No. 1, 2003.	
	21. "A two way cross over bioequivalence study for two	
	formulations (100 mg suppository) containing indomethacin and	
	treatment monitoring" Sabah H. Akrawi* and Haidar F. Hadi. J.	
	Appl. Sci., Vol. 7, No. 1, 38-47, 2005	
	22. "Solid State NMR and Bioequivalence Comparison of the	
	Pharmacokinetic Parameters of Two Formulations of Clindamycin"	
	Zeyad A. Al-Talla1, Sabah H. Akrawi and Abdul-Hamid Emwas, J.	
	Clinical Therapeutics, Vol. 49-No. 7/2011.	
	23. Bioequivalence assessment of two formulations of ibuprofen,	
	Zeyad A. Al-Talla1, Sabah H. Akrawi, Luke T. Tolley, Salim H.	
	Sioud, and and Abdul-Hamid Emwas, J. Drug Design,	
	Development and Therapy, 2011:5 427-433.	
	24. "Pharmacokinetic Interaction between Dietary Black Tea and	
	Carbamazepine in Epileptic Patients' Sabah H. Akrawi, Muna J.	
	Hadi, Yasir Ibranim, and Saban Al-Dabbagh; Latin American	
	Journal of Pharmacy, 34 (4), pp /54-9, 2015.	
Professional Studi		
i rolessioliai Stuur	Professional Studies: (As a principal investigator and head of the analytical	
laboratory)		
	1. Bioavailability – Bioequivalency study of formulations	
	1. Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study</li> </ol>	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.</li> </ol>	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol, 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study</li> </ol>	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1997.</li> </ol>	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1997.</li> <li>Two - Way, Crossover Randomized Bioequivalence Study of</li> </ol>	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1998.</li> <li>Two – Way, Crossover Randomized Bioequivalence Study of Two Formulations Containing 5mg Glibenclamide (Tablet), 1998.</li> </ol>	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1997.</li> <li>Two - Way, Crossover Randomized Bioequivalence Study of Two Formulations Containing 5mg Glibenclamide (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations</li> </ol>	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1998.</li> <li>Two – Way, Crossover Randomized Bioequivalence Study of Two Formulations Containing 5mg Glibenclamide (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 250 mg naproxen (Tablet), 1998.</li> </ol>	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1998.</li> <li>Two – Way, Crossover Randomized Bioequivalence Study of Two Formulations Containing 5mg Glibenclamide (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 250 mg naproxen (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations</li> </ol>	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1998.</li> <li>Two - Way, Crossover Randomized Bioequivalence Study of Two Formulations Containing 5mg Glibenclamide (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 250 mg naproxen (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 500 mg naproxen (Tablet), 1998.</li> </ol>	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1997.</li> <li>A two - Way crossover Bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1998.</li> <li>Two – Way, Crossover Randomized Bioequivalence Study of Two Formulations Containing 5mg Glibenclamide (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 250 mg naproxen (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 500 mg naproxen (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations</li> </ol>	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1998.</li> <li>Two – Way, Crossover Randomized Bioequivalence Study of Two Formulations Containing 5mg Glibenclamide (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 250 mg naproxen (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 500 mg naproxen (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Indomethacin as suppository , 1999.</li> </ol>	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1998.</li> <li>Two - Way, Crossover Randomized Bioequivalence Study of Two Formulations Containing 5mg Glibenclamide (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 250 mg naproxen (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 500 mg naproxen (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Indomethacin as suppository , 1999.</li> <li>Bioavailability – Bioequivalency study of formulations</li> </ol>	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1998.</li> <li>Two - Way, Crossover Randomized Bioequivalence Study of Two Formulations Containing 5mg Glibenclamide (Tablet), 1998.</li> <li>Bioavailability - Bioequivalency study of formulations containing 250 mg naproxen (Tablet), 1998.</li> <li>Bioavailability - Bioequivalency study of formulations containing 500 mg naproxen (Tablet), 1998.</li> <li>Bioavailability - Bioequivalency study of formulations containing 100 mg Indomethacin as suppository , 1999.</li> <li>Bioavailability - Bioequivalency study of formulations containing 100 mg Indomethacin as capsule, 1999.</li> </ol>	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1998.</li> <li>Two – Way, Crossover Randomized Bioequivalence Study of Two Formulations Containing 5mg Glibenclamide (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 250 mg naproxen (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 500 mg naproxen (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Indomethacin as suppository , 1999.</li> <li>Bioavailability – Bioequivalency study of formulations containing 25 indomethacin as capsule, 1999.</li> <li>Bioavailability – Bioequivalency study of formulations</li> </ol>	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1998.</li> <li>Two – Way, Crossover Randomized Bioequivalence Study of Two Formulations Containing 5mg Glibenclamide (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 250 mg naproxen (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 500 mg naproxen (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Indomethacin as suppository , 1999.</li> <li>Bioavailability – Bioequivalency study of formulations containing 25 indomethacin as capsule, 1999.</li> <li>Bioavailability – Bioequivalency study of formulations containing 25 mg Clomipramine as tablet, 1999.</li> </ol>	
	<ol> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Atenolol , 1994.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsules). 1997.</li> <li>A two - way crossover bioavailability - bioequivalence study for formulations containing cephalexin (capsule). 1998.</li> <li>Two – Way, Crossover Randomized Bioequivalence Study of Two Formulations Containing 5mg Glibenclamide (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 250 mg naproxen (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 500 mg naproxen (Tablet), 1998.</li> <li>Bioavailability – Bioequivalency study of formulations containing 100 mg Indomethacin as suppository , 1999.</li> <li>Bioavailability – Bioequivalency study of formulations containing 25 indomethacin as capsule, 1999.</li> <li>Bioavailability – Bioequivalency study of formulations containing 25 mg Clomipramine as tablet, 1999.</li> <li>Bioavailability – Bioequivalency study of formulations</li> </ol>	

	11. Bioavailability – Bioequivalency study of formulations	
	containing 250 mg methyldopa as tablet, 1999.	
	12. Bioavailability – Bioequivalency study of formulations	
	Containing 500 mg ampiciliin, capsules 1999.	
	containing 150 mg clindamycin cansules 1999	
	14. A bioequivalence study for two formulations containing	
	carbidopa/levodopa tablets; 2000.	
	15. A bioequivalence study for two formulations containing	
	gliciazide 80 mg tablets; 2000.	
	clindamycin 150 mg capsules: [Clindox <sup>®</sup> vs. Dalacin C <sup>®</sup> ]: 2001.	
	17. A bioequivalence study for two formulations containing	
	rifampicin 150 mg capsules; 2001.	
	18. A bioequivalence study for two formulations containing	
	ritampicin 300 mg capsules; 2001.	
	ibuprofen 100 mg suspension · 2001	
POST GRADUATE STUDIES AND SUPERVISION (Supervised the following		
research)		
	1. "Two–Way, Crossover Randomized Bioequivalence Study of	
	Two Formulations Containing rifampicin", Alaa Abbas & Sabah	
	Akrawi, Thesis, 2001.	
	2. "Effect of hepatic blood flow on diurnal variation of CBZ steady	
	state level during chronic portal vein infusion in rats". Abdula Al	
	Dhaw, Sabah Akarwi and P.J. Wedlund, 2000.	
	3. "Lisinopril versus Captopril in hypertensive patients with and	
	without renal impairment". Delshad Nori, Ali Farag Al-Saleh and	
	Sabah Akrawi , 2000.	
	4. "The effect of prednisolone and antibiotic treatment on sperm	
	function test and sperm agglutination in infertile men", Hiwa K.	
	Saeed, M.T. Albarzanchi and Sabah Akrawi, Thesis, 1999.	
	5 "Determination of nifedinine concentration in human serum"	
	Sahar M Ali and Sahah Akrawi Thesis 1999	
	6 "Two_Way Crossover Randomized Bioequivalance Study of	
	T E 14 O 4 C C C C C C C C C C C C C C C C C	
	I wo Formulations Containing Smg Glibenclamide and Treatment	
	Monitoring", Niazy B. Al-Deen and Sabah Akrawi, Thesis, 1999.	

7	7. "The bioavailability-bioequivalency study of two dosage forms of
1	test indomethacin product (25 mg capsules & 100 mg suppositories)
	and the treatment monitoring on patients using it", Haidar F. Hadi
4	and Sabah Akrawi, 1999.
8	3. "A two-way crossover bioavailability - bioequivalence study for
t	formulations containing cephalexin". Qais N. Khammas and Sabah
	Akrawi, Thesis, 1998.
9	9. "Drug registration system". Hana Y. Kinno and Sabah Akrawi,
ŗ	Thesis 1998.
1	0. "Therapeutic drug monitoring for a test product containing 100mg
	atenolol and its bioavailability", Fadia Yaqub and Sabah Akrawi,
ŗ	Thesis, 1998.
1	1. "Comparative study of three different manufacturers of atenolol
1	tablets in hypertensive patients", Saleh A. Al-Rawi and Sabah
	Akrawi, Thesis 1997.
12	2. "Possible drug interaction between carbamazepine and tea
	components in human". Muna J. Hadi and Sabah Akrawi, Thesis
	1996.
1	3. "Prescribing errors in selected Hospital and Private Clinics in
]	Baghdad". Niazy Burhanaddin and Sabah H. Akrawi. 1996.
14	4. "Characterization of diurnal variation during chronic intravenous
i	infusion of carbamazepine in rats". Sufyan A. Abdullah and Sabah
	Akrawi, Thesis 1995.
1.	5. "Prescribing errors in hospitals and private clinics in Kurkuk
	city", Neyazy Burhanaddin and Sabah Akrawi, Thesis 1994.
1	6. "Determination of renal stone's type affected by Prosopis Farcta
]	leaves extract", Asma O. Al-Naje and Sabah Akrawi, Thesis 1994.
1	7. "Nosocomial infections in three of Erbl's Hospitals". Kawa F.
]	Dizayee and Sabah Akrawi, Thesis 1993.

### SCIENTIFIC RESEARCH AND ACTIVITIES

	1. Establish Bioequivalence Studies Unit (principal investigator
	and head of the analytical laboratory) at the College of Pharmacy.
	University of Baghdad (1992).
	2. Establish Bioequivalence Studies Unit and the (principal
	investigator and head of the analytical laboratory) at the College of
	Pharmacy – Applies Science University (2000)
	3 A principal investigator and head of the analytical laboratory
	for many (19) Bioequivalence Studies.
	4Teaching Clinical Pharmacy, Applied Therapeutic, Clinical
	Pharmacokinetic. Metabolism and OTC Drugs courses to pharmacy
	students (under graduate and post graduate) at Universities of
	Baghdad, and Applied Science University.
	5. Teaching Pharmacokinetic. Biopharmaceutic and Physical
	Pharmacy courses to pharmacy students (under graduate and post
	graduate) at Universities of Baghdad and Applied Science University
	6 Supervising (17) post graduate students for M Sc and
	Diploma degree in area of Biopharmaceutics and clinical pharmacy at
	the College of Pharmacy University of Baghdad
	7 Participating in teaching short courses of many Continuing
	Education programs at the Ministry of Health
	8 Editorial secretary of the "Iraqi Journal of Pharmaceutical
	Sciences" published by College of Pharmacy University of Baghdad
	(1994-2000)
	9. Publishing (22) Scientific Papers in Local and International
	Journals.
	10. Using Computer Programs (WinNonMix, Window, Excel
	Microsoft and SPSS).
	11. I Performed and have Good experience in doing Chronic
	Intrahepatic Drug Infusion in Unrestraine animals (published in the
	journal of pharmacological methods (1987).
	12. Performed the following:
	Determination of Drugs Concentration in human and animal blood
	Micro Samples using HPLC & GC technique.
	Design and Supervise the clinical part of the Bioequivalence studies.
	Perform and Validate the Analytical Methods of the Bioequivalence
	studies.
	Design and Supervise drug Disposition studies for drugs in order to
	evaluate its pharmacokinetics parameters (Clearances, Volume of
	Distribution, Rate of elimination, Half-life etc.)
	Study the metabolism of drugs and its Stereoselective disposition.
	Design and Supervise study for the Drug-Food interaction.
PROFESSIONA	L ASSOCIATIONS and MEMEBRSHIP
1999-2000	A <u>Member</u> of the Drug Registration Committee (responsible for the
	bioequivalence studies evaluation), Ministry of health (1999-2000).

	<u>A member</u> of the Iraqi Scientific Pharmaceutical Association.
	Rho Chi, Pharmaceutical Honor Society
1989-2000	<u>A member</u> of several Consultant Scientific Committees of the Ministry of Health, Baghdad.
1997-2000	A <u>Member</u> of the scientific committee for Drug Industry (responsible for the GMP evaluation), Ministry of health.
LANGUAGES	
English	Read, write and speak fluently.
Arabic	Read, write and speak fluently.